Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.

about

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?

P2860

Q55513059-C03C8D54-4863-4C58-9EC2-A868D8B9D28D Q58799265-DBB6A761-3DB0-4A3C-8EE5-24C84D6FB944

P2860

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.

Item

http://www.wikidata.org/entity/Q38620187

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.

@en

type

Item

label

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.

@en

prefLabel

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.

@en

P1476

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis

@en

P2093

Belal Firwana

http://www.w3.org/2001/XMLSchema#string

Diana Almader-Douglas

http://www.w3.org/2001/XMLSchema#string

Issam Makhoul

http://www.w3.org/2001/XMLSchema#string

Mitesh J Borad

http://www.w3.org/2001/XMLSchema#string

Ramesh K Ramanathan

http://www.w3.org/2001/XMLSchema#string

Tanios Bekaii-Saab

http://www.w3.org/2001/XMLSchema#string

Zhen Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Cancer statistics, 2016

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.

S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.

P304

4680-4686

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1002/CNCR.30927

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Mohamad Bassam Sonbol

Daniel H Ahn

P577

2017-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28817187

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.

about

P2860

P2860

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921